Group 1 - Nan Mining Group signed a procurement contract for iron ore equipment worth 3 billion yuan with Lanyan Weiye Mineral Processing Co., Ltd., for a project processing over 4.6 million tons of ore annually, with an estimated operational cost of 3 billion yuan over 10 years [1] - Guangdong Yuedian A's Dapu Power Plant Phase II Project's Unit 4 has commenced commercial operation, with a total investment of 8.122 billion yuan and an expected annual power generation of 9 billion kilowatt-hours [2] - China Energy Engineering's subsidiary won an EPC general contracting project in Shaanxi Province with a bid amount of approximately 6.864 billion yuan, covering ecological governance, infrastructure, urban renewal, and water conservancy projects, with a total construction period of 36 months [3] Group 2 - ST Dongtong's stock will resume trading on December 30, 2025, entering a delisting arrangement period of 15 trading days, with the last trading date expected to be January 21, 2026 [4] - Roman Co.'s subsidiary signed a contract for a computing power service project worth approximately 156 million yuan with Tianjin Maoyuan Equipment Leasing Co., Ltd. and China Merchants Intelligent Supply Chain Service Co., Ltd. [5] - Hangzhou Thermal Power plans to sign a three-year coal purchase contract with Shanghai Yitai Shenpu for a total of 9 million tons, ensuring stable coal supply from 2026 to 2028 [6] Group 3 - Caitong Securities received approval from the China Securities Regulatory Commission to publicly issue bonds totaling no more than 15 billion yuan [7] - Qipai Technology's application for a stock issuance to specific investors has been approved by the Shanghai Stock Exchange [8] - China Software plans to sell 555 units of X86 servers and two properties to optimize idle assets, with a total estimated value of approximately 6.758 million yuan [10] Group 4 - Xinhua Medical received medical device registration certificates for two products, including an interleukin-6 test kit and a dual test kit for procalcitonin/interleukin-6 [11] - Shandong Haohua announced the resignation of Deputy General Manager Yuan Falin due to personal reasons [12] - Haixiang Pharmaceutical's invested company NWRD06 injection has completed the enrollment of the first subject in its Phase II clinical trial [13] Group 5 - Tiantong Co. terminated the absorption merger of its wholly-owned subsidiary Tiantong Rijing Precision Technology Co., Ltd., retaining its independent legal status [14] - Ruima Precision's subsidiary received a project designation for automotive air suspension systems, with an estimated sales revenue of approximately 1.342 billion yuan over a six-year lifecycle [15] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Qianxing Future to enhance collaboration in the development and manufacturing of quadruped robots [16] Group 6 - Huali Co. terminated the acquisition of a 51% stake in Zhongke Huilian due to failure to reach consensus on key transaction terms [17] - Acolyte's olefin copolymer has passed customer verification and is now in bulk supply for the optical lens sector [18] - Tianjian Technology signed a supplementary agreement for military product price adjustments, expecting a revenue reduction of approximately 256 million yuan [19] Group 7 - Southeast Network Framework won an EPC project bid for the "China Vision Valley Industrial Base" with a total bid amount of 888 million yuan [20] - Baodi Mining plans to acquire 87% of Congling Energy for a total of 685 million yuan through a combination of cash and share issuance [21] - Heng Rui Pharmaceutical received clinical trial approval for multiple drugs, including HRS-6257 tablets for treating acute and chronic pain [22] Group 8 - Zhongxin Saike received a dividend of 60 million yuan from its wholly-owned subsidiary [23] - ST Songfa's subsidiary signed a contract for the construction of an oil tanker with a total contract value of approximately 80 to 100 million USD [24] - China Resources Double Crane received clinical trial approval for hydroxocobalamin injection, aimed at treating metabolic disorders in children [25][26]

Core Viewpoint - China Resources Double Crane (华润双鹤) has received approval from the National Medical Products Administration for clinical trials of Hydroxocobalamin Injection, aimed at treating metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1] Group 1 - The company announced the receipt of the clinical trial approval notice on December 29 [1] - Hydroxocobalamin Injection is specifically indicated for pediatric patients suffering from metabolic disorders related to methylmalonic acidemia [1] - This development may enhance the company's product portfolio in the pediatric therapeutic area [1]

Core Viewpoint - The company has received the clinical trial approval notice for Hydroxocobalamin Injection from the National Medical Products Administration, indicating progress in its drug development efforts [2] Group 1: Drug Development - Hydroxocobalamin Injection is intended for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [2] - The total research and development investment for this drug has reached RMB 13.0581 million (unaudited) as of the date of the announcement [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of Hydroxocobalamin injection, indicating progress in its drug development pipeline [1] Group 1: Regulatory Approval - The company announced on December 29 that it received the clinical trial approval notice for Hydroxocobalamin injection from the National Medical Products Administration [1] - The acceptance notice for the drug was received on October 22, 2025, and the clinical trial approval was granted on December 25, 2025 [1] Group 2: Financial Investment - As of the date of the announcement, the company has invested a total of RMB 13.0581 million (approximately 1.3 million) in the research and development of this drug [1] Group 3: Indication - Hydroxocobalamin injection is indicated for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1]

Core Viewpoint - China Resources Double Crane (600062.SH) has received the clinical trial approval notice from the National Medical Products Administration for Hydroxocobalamin Injection, indicating a significant step in the development of this treatment for metabolic disorders in children [1] Group 1 - The approved drug, Hydroxocobalamin Injection, is intended for the treatment of methylmalonic acidemia with or without homocystinuria in pediatric patients [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of Hydroxocobalamin injection, indicating progress in its drug development pipeline [1] Group 1: Regulatory Approval - The company received the clinical trial approval notice for Hydroxocobalamin injection on December 25, 2025, after the acceptance notice on October 22, 2025 [1] - The approval is significant for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1] Group 2: Research and Development Investment - The total R&D investment for Hydroxocobalamin injection has reached RMB 13.0581 million (unaudited) as of the date of the announcement [1]